Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: PROCEDURE: Positron emission tomography (PET)|DRUG: Trastuzumab|DRUG: Pertuzumab
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Translational Breast Cancer Research Consortium|Genentech, Inc.